Rod Raynovich Blog | Talkmarkets | Page 1
CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more

Articles

Latest Posts
1 to 16 of 229 Posts
1 2 3 ... 15
Biopharma Stocks Rally And Gene Therapy Stocks Are Still Hot
Mid-Cap biotech stocks ran up today along with a broad market rally in tech stocks with the NAZ up 1.42% and the XLK​ up 2.51%.
Biotech Stocks Hold After Brief Sell-Off Last Week…Updates
Biotech ETFs lost momentum last week but held near term support near the 20 Day moving average. Now that most companies have reported we should not expect fundamentals to create volatility.
Sideways Market Vexes Traders: Biotech Stocks Are Fading
The 2019 rally is fading with few clues as to what comes next. The narrative gets more complicated once a slower global economic outlook gets factored into the fundamentals.
Small Cap Biotechs Lead The Market In 2019 Up 20% YTD
Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%.
HH Biotech Bear Market: But Is It Time To Start Trading?
The Nasdaq is down 1.6% and the Russell 2000 is down 1.8%, killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. Healthcare still looks good overall with the XLV down only 0.29% at $92.95.
Biotech Bull Market Under Pressure: Now Flat To Down In 2018
Here are some positive and negative indicators to consider on the future direction of biotechnology stocks.
Biotech Snapshot: Healthcare Sector Remains Strong
FBT down 0.75% at $151.78, IBB down 0.58% at $117.32, XBI down 0.64% at $96.08.
Biopharma Portfolio 2018 YTD: Performance Summary
The best way to make money in biotechnology is to hold the best companies over the long-term.
Biotech Snapshot During A Rally Day: No Summer Doldrums…
Biotech stocks were mixed trading closer to the flatline after the close last night, on light summer volume. Macro issues such as drug pricing, trade and the Fed remain a concern.
Q2 Earnings Update: Bluebird Bio (BLUE) And Regeneron (REGN)
Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. Bluebird Bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue.
Biotechs Hold And Ignore Rocky Week Of Global Politics - Big Earnings Upcoming… Updates CELG, BIIB, AZN, XBI
Biotech and Tech stocks teetered near highs for the year despite all the political drama of Putin and Trump at Helsinki, Russian “Spy” at the NRA, Tariffs and Trade War, Brexit Uncertainty, currency volatility and the Powell FED rate hike policy.
Biotechs Cruise Onto Green Screen: July Looks Good
Biotechs cruised through the choppy market of late June to rally with many mid-caps rolling up and major ETFs up creeping toward 2018 highs. However, with earnings reports coming up, we could expect some selling depending on top line growth.
Biotech Rally Buffeted By Trump Tweet But Gains Hold
The Biogen catalyzed rally has stalled on another tweet on drug pricing from POTUS.
Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform
Biotechs soared Friday immediately after Trump’s much-anticipated new drug plan speech which was going to address high drug prices and potentially bring more government intervention.
Biotech Stocks Underperform Market: CELG, EXEL, PBYI, XBI
Biotechs underperformed despite a good opening with the XBI trying to break through the SMA 50 level but fell back around mid-day.
Biotechs Survive 2018 Bottom And Catch A Rally
The overall market rallied Friday with good strength in Nasdaq up 1.71 % and the QQQ even better, up 1.9% helped by AAPL up 3.97% on a huge buy program this week by Berkshire-Hathaway.
1 to 16 of 229 Posts
1 2 3 ... 15